Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

John Averette

Physician Assistant Asheville, NC Physician Assistant

NPI 1689139768 CMS profile 10449108

119 Tunnel Rd Ste D, Asheville, NC 28805

Open in the dashboard

General payments

$34,082

219 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Averette of Asheville, NC is reported in the CMS Open Payments database as having received $34,082 across 219 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $413 24
2024 General $4,686 46
2023 General $28,025 93
2022 General $639 34
2021 General $319 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Averette
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to John Averette were reported at $413. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year John Averette Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $319 $132 $37–$438 $132
2022 $639 $155 $48–$522 $149
2023 $28,025 $167 $52–$557 $160
2024 $4,686 $178 $55–$600 $164
2025 $413 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $31,966 95 payments
  2. ITI, Inc. $530 34 payments
  3. Otsuka America Pharmaceutical, Inc. $393 25 payments
  4. Alkermes, Inc. $376 16 payments
  5. Vanda Pharmaceuticals Inc. $303 19 payments
  6. Teva Pharmaceuticals USA, Inc. $115 6 payments
  7. Axsome Therapeutics, Inc. $106 3 payments
  8. Indivior Inc. $88 5 payments
  9. Sunovion Pharmaceuticals Inc. $71 7 payments
  10. E.R. Squibb & Sons, L.L.C. $62 4 payments
  11. Other $72 5 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $26,775 20 payments
  2. Travel and Lodging $3,810 21 payments
  3. Food and Beverage $3,442 176 payments
  4. Education $55 2 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR $31,966 95 payments
  2. CAPLYTA $515 33 payments
  3. ARISTADA Cns $361 15 payments
  4. ARISTADA Cns $361 15 payments
  5. ABILIFY MAINTENA $329 21 payments
  6. ARISTADA Cns $307 12 payments
  7. ARISTADA Cns $307 12 payments
  8. FANAPT $303 19 payments
  9. ARISTADA INITIO $234 8 payments
  10. LYBALVI $195 11 payments
  11. Other $1,047 60 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 42 drugs

Part D claims

1,672

Median for Physician Assistant: 241

Drug cost

$430,291

Median for Physician Assistant: $4,110

Branded share of claims

27%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 77 $111,276
Invega Sustenna Paliperidone Palmitate Brand 33 $103,746
Lybalvi Olanzapine/Samidorphan Malate Brand 46 $65,553
Aristada Aripiprazole Lauroxil Brand 17 $55,461
Abilify Maintena Aripiprazole Brand 14 $43,442
Sublocade Buprenorphine Brand 11 $22,208
Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine Brand 44 $3,118
Trazodone Hcl Generic 139 $2,076
Gabapentin Generic 144 $2,036
Olanzapine Odt Olanzapine Brand 22 $1,857

The 10 drugs with the highest cost, of 42 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $4,196
$4,196 77 —
CAPLYTA
  • ITI, Inc. $145
$145 — —
FANAPT
  • Vanda Pharmaceuticals Inc. $92
$92 — —
ABILIFY MAINTENA
  • Otsuka America Pharmaceutical, Inc. $80
$80 14 —
Auvelity
  • Axsome Therapeutics, Inc. $65
$65 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

219 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record